PSO17CSF Study in Motor Neuron Disease

Phase I/II study of PSO17CSF in patients with motor neuron disease - PSO17-MND

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2011220046

Enrollment

Registered

2023-03-25

Start date

2023-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

motor neuron disease

Interventions

Intrathecal injection of 10mL or 15mL or 20mL of PSO17CSF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Over 18 years old when informed consent is obtained. (2) Patients with motor neuron disease. (3) The patients scheduled for lumbar puncture. (4) Written informed consent is obtained after sufficient explanation and full understanding.

Exclusion criteria

Exclusion criteria: (1) Contraindication for MRI such as metallic implant, tattoo in the body. (2) Severe lumbar canal stenosis. (3) Currently enrolled in another research. (4) Previous history of drug allergy (5) Serious disease of liver, kidney, heart, etc. (6) Current or planned pregnancy. (7) The patients with lesions on MRI scan in the previous observation period (except when the investigator determines that there is no problem with participation in the clinical trial). (8) Any other reason judged by a clinical trial doctor that renders the candidate unsuitable for this clinical trial.

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
change in MRI signal intensity. safety	—

Contacts

Public ContactNaoko Okita

Hokkaido University Hospital

PSO17-06_jimu@pop.med.hokudai.ac.jp+81-11-706-7923

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026